Acute myeloid leukemia (AML) blasts are immature committed myeloid cells unable to spontaneously undergo terminal maturation, and characterized by heterogeneous sensitivity to natural differentiation inducers. Here, we show a molecular signature predicting the resistance or sensitivity of six myeloid cell lines to differentiation induced in vitro with retinoic acid or vitamin D. The identified signature was further validated by TaqMan assay for the prediction of response to an in vitro differentiation assay performed on 28 freshly isolated AML blast populations. The TaqMan assay successfully predicts the in vitro resistance or responsiveness of AML blasts to differentiation inducers. Furthermore, performing a metaanalysis of publicly available microarray data sets, we also show the accuracy of our prediction on known phenotypes and suggest that our signature could become useful for the identification of patients eligible for new therapeutic strategies.
Introduction
The sensitivity of acute myeloid leukemia (AML) to vitaminmediated differentiation induction is strictly dependent on the specific maturation arrest of the AML blasts and on specific (cyto)genetic alterations. Acute promyelocytic leukemia (APL) (French-American-British classification (FAB), M3 type) is in vitro and in vivo sensitive 1 to the maturation effect of alltrans retinoic acid (ATRA). AML blast cells with M2 phenotype carrying the t(8;21) undergo monocyte maturation after treatment both with ATRA or vitamin D3 (VD). 2 In contrast, myeloblasts with M0 or M1 phenotypes are refractory, with few exceptions, to the maturation activity of differentiation inducers. A differentiating therapy could be useful also in other types of AML, 3, 4 but unfortunately, apart from APLs, the heterogeneous effect on leukemic cells makes it extremely difficult to predict the clinical impact of the differentiation induction therapy on the single patient. 5 Therefore, the standard parameters used for morphological, immunophenotypic or cytogenetic classification of AMLs do not allow, especially in early myeloblasts, the prediction of their sensitivity or resistance to differentiation inducers. Gene expression profiling (GEP) using microarray technology has become a powerful tool for classifying hematopoietic neoplasms. 6 In AMLs, GEP showed the capability to classify the established genetic subsets of AML, as well as to identify particular subclasses of AML associated with unfavorable outcome of treatment that are not disclosed by standard cytogenetic and molecular analyses. [7] [8] [9] [10] [11] [12] [13] [14] [15] Specifically, Heuser et al. 16 has recently described for the first time a gene expression signature of chemotherapy-resistant AML patients. So far, none of the available data allows the prediction of the AML's response to differentiating therapy. Several leukemic cell lines have been derived by cell populations and are still characterized by the same immunophenotype, maturation arrest and inability to spontaneously undergo terminal maturation. [17] [18] [19] [20] [21] They also retain a different sensitivity or resistance to ATRA and VD, 2, 22, 23 whereas they differ from the original spontaneous blast cells by a high proliferation rate. Thus, looking for expression patterns characterizing resistance or sensitivity to differentiation therapy, we initially profiled by GeneChip arrays the gene expression of several AML cell lines. Here, we show that differences exist in prediction of the cell line differentiation fates. Then, we constructed a signature able to predict resistance or sensitivity to the differentiation induction. Using a TaqMan platform, we successfully tested it for its capability to predict the in vitro response of 28 VD-or ATRA-treated freshly isolated AML blast cell populations. Finally, we performed a meta-analysis of publicly available microarray data. In this way, we tested the accuracy of our classifier and suggest a possible new tool for the identification of patients eligible for new therapeutic strategies.
Materials and methods

Cell lines and patients' samples
KG-1 and KG-1a (early myeloblasts, M0/M1 type of AMLs), Kasumi-1 and THP-1 cells (M2 and M5 types of AMLs, respectively), HL-60 and NB4 cells (M2/M3 types AMLs) were obtained from The American Type Culture Collection and cultured as described previously. 24 The phenotype of each cell line was defined by morphological analysis. Immunophenotyping was performed by flow cytometry as already described. [25] [26] [27] Cell lines differentiation was induced by treatment with either 10 À6 M ATRA (Sigma Chemical Co., St Louis, MO, USA) or 10 À7 M VD3 (La Roche, Basel, Switzerland) as described previously. 25, [28] [29] [30] The differentiation was monitored after 5 days by direct immunofluorescence analysis as already described. [25] [26] [27] 31 At disease onset, AML blasts were obtained, upon informed consent, from the peripheral blood of 28 patients who showed X85% leukemic infiltration. Blasts were isolated by centrifugation on a Ficoll-Hypaque gradient and treated in vitro with ATRA or VD as described above. Differentiation was monitored by direct immunofluorescence analysis as already described. [25] [26] [27] 31 GEP and data analyses Total cellular RNA was isolated before inducing differentiation either from two independent lots of each cell line or from AML blasts, using RNeasy RNA isolation kit (Qiagen, Valencia, CA, USA) following the manufacturer's recommendations. Disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) were used to determine the concentration and purity/integrity of RNA samples using Agilent 2100 bioanalyzer. cDNA synthesis, biotin-labeled target synthesis, HG-U95Av2 GeneChip (Affymetrix, Santa Clara, CA, USA) arrays hybridization, staining and scanning were performed according to the standard protocol supplied by Affymetrix. The amount of a transcript mRNA (signal) was determined by the MAS 5.0 absolute analysis algorithm as already described. 32 All expression values for the genes in the MAS 5.0 absolute analyses were determined by using the global scaling option. Alternatively, probe level data were converted to expression values using robust multi-array average (RMA) procedure. 33 Perfect match values were background adjusted, normalized using invariant set normalization and log transformed. The RMA-generated data were uploaded onto GeneSpring software version 7.2 using the log 2 transformation procedure. A 'per gene' normalization was achieved by dividing each signal by the median of its values in all samples. A low-level filter in GeneSpring filtered out all those probesets called 'Present' in less than 10% of samples or whose normalized expression levels were always between 0.5 and 2 across all of the samples. Affymetrix MAS 5.0 comparison algorithm 32 was used for supervised analysis selecting those transcripts showing a change call 'I' or 'D' in at least 90% of the pairwise comparisons. Supervised analyses were performed using an analysis of variance (ANOVA) test (Welch ANOVA at a confidence level of 0.01) with the Benjamini and Hochberg correction of the false discovery rate, and using dChip Compare Sample procedure. 34, 35 Briefly, the comparison criteria utilized in dChip require the fold change and the absolute difference between two group means to exceed user-defined thresholds (in the present study, three and 200, respectively). The 'use lower 90% confidence bound' has been selected to use the lower confidence bound of fold changes for filtering. 34, 35 The lower confidence bound is intended as a conservative estimate of the real underlying fold change. False discovery rate (FDR) has been used to adjust P-value for multiple comparisons by 100 random permutations of the group labels. The GeneSpring advanced filtering options were used to combine gene lists generated from different analyses. Hierarchical agglomerative clustering of the selected probe lists was performed using GeneSpring. Class prediction analyses were performed using the Support Vector machine algorithm as implemented in GeneSpring (Polynomial Dot Product (Order 1) Kernel Function. Diagonal Scaling Factor: 0).
Real-time quantitative PCR
cDNAs were reverse transcribed from total RNA samples (100 ng per sample) using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) as described in the manufacturer's protocol. TaqMan PCR reactions were carried out from cDNA samples using custom TaqMan low-density arrays (Applied Biosystems, Foster City, CA, USA) by means of ABI PRISM 7900 HT Sequence Detection Systems. GEP was achieved using the comparative CT method of relative quantification. In order to normalize data, delta-delta-CT was calculated for each detector using as calibrator the median of its delta-CTs in all samples. Normalized delta-delta-CTs were then uploaded onto GeneSpring using the real-time data transformation.
Results
In vitro differentiation of myeloid leukemic cell lines with ATRA or VD
The sensitivity of AML cell lines to ATRA and VD was tested in vitro as described in Materials and methods. The leukemic progenitors, KG-1a and KG-1, are refractory to the induction of differentiation with both agents. Kasumi-1 cells undergo monocytic differentiation after treatment either with ATRA or VD. THP-1 cells differentiate along the mono-macrophagic pathway following stimulation with VD. NB-4 cells are able to achieve granulocytic differentiation following stimulation with ATRA and do not respond to VD. Finally, HL60 cells are sensitive to both ATRA and VD, achieving granulocytic and monocytic differentiation, respectively. These data fully confirm the results already reported 2, 25, 30, 36 and are summarized in Table 1 .
GEP data analysis Unsupervised clustering identifies, among AML cell lines, three main groups in relation to their differentiation capability. Using an unsupervised hierarchical clustering approach, we tried to define natural subclasses of samples as determined by gene expression profiles. We performed the unsupervised clustering on a low-level filtered probe list using the Pearson correlation equation. The clustering results are shown in Figure 1 . Interestingly, three main classes were defined: the first includes the 'early myeloblast', resistant cell lines (KG-1a and KG-1), the second consists of the 'late myeloblast (LM)/monoblast' cell lines, inducible to monomacrophage differentiation (Kasumi-1 and THP-1), and the third includes the 'LM/promyelocyte' (PR) cell lines, inducible prevalently to granulocyte maturation (HL-60 and NB-4).
A molecular signature distinguishes sensitivity to differentiation agents. In order to stringently identify genes that might represent the molecular signature of sensitivity or resistance to differentiation induction, namely to select which genes have a higher discrimination power between the groups previously identified by unsupervised analysis, we employed two different approaches. Specifically, an ANOVA test was applied to the probe list coming from the first supervised filter based on MAS 5.0 comparison analysis as described in Materials and methods. The ANOVA analysis led to the identification of 209 significant probesets. Moreover, dChip Compare Sample procedure 34, 35 allowed the identification of 150 significant probesets, with an overall median FDR of 0.8% (90th percentile FDR of 6.7%). Probesets passing both analyses (111 probesets, corresponding to 97 transcripts) were selected as the 'signature' gene list (Figure 2 ). The annotated gene list is shown in Table 1S (supplementary material).
TaqMan low-density arrays successfully validate the signature on cell lines population. In order to validate microarray data, we designed, using the 'signature' gene list, a TaqMan low-density array containing in quadruplicate 47 þ glyceraldehyde-3-phosphate dehydrogenase TaqMan gene expression assays that were available at the time of experiment on the Applied Biosystems catalog (the TaqMan assays' list is shown in Table 2S , supplementary material). This TaqMan panel was then tested on the same RNAs used to perform the array experiment. The correlation between array and TaqMan data was greater than 95%. Figure 1S (supplementary material) shows the clustering of array and TaqMan data.
TaqMan low-density arrays successfully validate the signature on freshly isolated leukemia population treated in vitro with ATRA and VD. In order to prove whether the obtained signature was able to predict the sensitivity to ATRA or VD also in blast cells isolated from leukemia patients, total cellular RNA was extracted from 28 freshly purified AML blast populations and the above-described TaqMan panel was tested. In order to identify the differentiation response classes by which they perform the supervised analysis, AML cell populations were treated in vitro with ATRA and VD at the same conditions used for the cell lines, and the achieved differentiation was monitored both morphologically and by flow cytometry ( Table 2) . A training set including TaqMan data obtained from all cell lines and from 10 AML blast cell populations was used to validate the microarray data. Specifically, the 10 blast cell populations were randomly selected among the 28 freshly purified AML cases, with the only criterion for selection being the presence of all classes of differentiation response. Using an unsupervised hierarchical clustering approach on this training set data, we demonstrated that again three main classes were defined, the first includes both cell lines and AML blast populations that do not respond to differentiation induction, whereas the second and the third consist of the responsive cell lines and AML populations (Figure 3) , respectively. An ANOVA analysis (parametric test, variances not assumed equal; t-test P-value cutoff 0.05) was performed on training set data in order to select genes that present statistically significant differences when the parameter 'response' to differentiation induction is tested. Eleven genes passed the analysis and were selected as predictor set (data not shown). The predictor set was then used to perform a class prediction analysis with the Support Vector Machine implemented in GeneSpring package using the remaining 18 AML samples as test set. Table 3 shows the results of the cross-validation of the training set as well as the prediction of the test set. No incorrect predictions were made in the cross-validation of the training set. Only two incorrect predictions were made analyzing the test set, even if incorrect predictions are related with the final phenotype of the differentiated populations and not with the sensitivity to differentiation induction.
A meta-analysis performed on publicly available AML GEP databases provides the possible clinical impact of the prediction of the differentiation induction sensitivity.
Assuming that our classifier was able to predict correctly the sensitivity to differentiation induction on our AML data set, we tested our predictor on publicly available AML GEP data sets with two main purposes: first to validate the accuracy of our prediction for M3 AMLs data, for which we can, by definition, assume the existence of a responsiveness to ATRA treatment, and second to hypothesize the possible clinical impact that a prediction of the sensitivity to differentiation agent can have on GEP and sensitivity to differentiating therapy E Tagliafico et al patient defined with a poor prognosis. To do so, we downloaded from public repositories both Valk's and Bullinger's AML GEP data sets. 10, 11 We uploaded them onto GeneSpring along with all tables describing clinical features and experimental findings. The HG-U133A probeset list corresponding to our previously described prediction set was then used to perform a class prediction analysis with the Support Vector Machine implemented in GeneSpring package, using microarray data obtained from cell lines as training set and Valk's or Bullinger's complete data sets as test sets. Tables 3S and 4S (supplementary materials) show the results of the prediction for Valk's and Bullinger's data sets. No incorrect predictions were made in both data sets in the prediction of M3 (t(15:17)) samples for which we predict a 'LM/ PR' class. For the remaining AML cases of Valk's and Bullinger's data set, where we are not able to establish the accuracy of the differentiation behavior prediction because no data are available about any differentiation treatment, we attempted to correlate our prediction with FAB classification, cytogenetics, molecular data and known prognosis classes. No correlations with statistical significance were found between the prediction of resistance or sensitivity to differentiation induction and risk factors like FMS-like tyrosine kinase 3 internal tandem duplication, renin-angiotensin system mutations or CCAAT/enhancerbinding protein-a mutations. Conversely, some significant findings came from the differentiation behavior prediction of AML cases already classified (in the studied databases) as poor prognosis (cluster no. 10, Figure 2 of Valk's paper 10 and patients showing the 'poor outcome' with Bullinger predictor 11 ). Most of these patients (about 80% for the Valk's data set and about 60% for the Bullinger's data set) (Tables 3S and 4S , supplementary materials) were assigned by our predictor, to the class of population resistant to differentiation induction. This means that these patients probably could not have gained benefit from a differentiating therapy. However, for a percentage of cases ranging from the 20 up to 40%, we assigned a class of sensitivity to maturation induction (LM or PR). This could suggest that a relevant percentage of patients with poor prognosis could have gained advantage from a differentiating therapy.
Discussion
Differentiation therapy is one of the most widely studied clinical topics of leukemia research. 37, 38 The lack of factors or tools predicting the response to differentiating agents (butyric acid, retinoids, VD3 analogs, dimethylsulfoxide, phorbol esters, valproic acid, etc.) leaves the clinical impact of this therapy so far highly heterogeneous in the large majority of AMLs. 5, 39 For this reason, we looked for the presence of some specific gene expression patterns, characterizing the sensitivity of different AMLs to differentiation induction. In fact, the ability to distinguish between the AMLs sensitive to pharmacological induction of differentiation and the resistant ones might become extremely useful to know whether or not those AMLs currently classified as 'poor prognosis' might benefit from the addition of a differentiating therapy.
As a model, we initially compared by GeneChip arrays the gene expression profiles of six AML cell lines characterized by different levels of immaturity and different sensitivity to VD or ATRA. The unsupervised analysis of GEP data clearly relates cell lines with similar differentiation ability: KG-1 and KG-1a, HL-60 and NB4 and Kasumi-1 and THP1 (Figure 1) . A peculiar observation, in agreement with our previous results, 2 is the demonstration that the expression profiles of Kasumi-1 and THP-1 cells are similar, in spite of the different immunophenotype (M2-type myeloblasts and M5 monoblasts, respectively). Then, two robust statistical filtering procedures allowed us to identify a signature with a high discrimination power among the resistant, the monocyte-inducible and the granulocyte-inducible groups. In order to validate the signature obtained from the cell lines' model, we tested in vitro the sensitivity to ATRA-or VD-induced maturation of 28 freshly purified leukemic blast cell populations. Before the induction of differentiation, RNA was extracted and a TaqMan panel built on the signature genes was tested with the purpose of proving its prediction power also on freshly purified AML blasts. An ANOVA analysis performed on TaqMan data obtained from the training set (cell lines and 10 AMLs blast cell populations) was used to validate the macroarray data obtained in cell lines. Eleven genes were selected significantly discriminating resistant cell lines and AMLs from the sensitive ones. The class prediction analysis performed, using these 11 genes as predictor gene list, on the 18 AMLs not included in the training set further confirmed that our predictor is able to predict correctly the sensitivity or the resistance to maturation induction. Interestingly, the sensitivity to the agents assumed for a FAB phenotype, in some cases, does not correspond to the sensitivity assayed in in vitro experiments. In these cases, the GEP predicts sensitivity or resistance correctly, and, in this way, is ultimately able to estimate the possible response to differentiation induction in a better way than FAB classifications. The introduction of GEP has filled important gaps in the classical diagnostic approach of AML patients. 10, 11 Bullinger et al.
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postulated two novel subgroups of leukemia with predominantly normal karyotypes associated with significant differences in survival times. Valk et al. 10 identified 16 clusters of homogeneous signatures, some of them not associated with known (cyto)genetic markers, as well as cases with a variety of known, but not common adverse cytogenetic markers, such as monosomies 7 and 5 and the translocation t (9;22) . Patients with these particular clusters showed an unfavorable treatment outcome. The use of these publicly available data sets, even if not complemented by information regarding the differentiation behavior of AML cases, allowed us to validate the accuracy of our prediction on t(15:17) phenotypes for which we can, by definition, assume the existence of a responsiveness to ATRA treatment. Thus, assuming that our classifier was able to predict correctly the sensitivity to differentiation induction, we tried to extend the prediction to all samples of data sets with the purpose of inferring the possible clinical impact of this prediction, that is, to estimate, for example, how many AMLs, already labeled as poor prognosis, could have gained benefit from a differentiating therapy. We observed that, even though our signature predicts the resistance to differentiation therapy for approximately 70% of patients belonging to clusters associated with a poor prognosis, about 30% of patients belonging to these clusters were assigned to a class of sensitivity to differentiation induction. This confirms the issue that, although for the majority of AMLs characterized by a bad outcome the differentiation block cannot be rescued using physiological differentiation agents, a significant subset of patients could actually gain benefit from a differentiating therapy. To conclude, considering that FAB or other classification are not sufficient for predicting the response to differentiation induction, our signature could represent a new tool for driving new treatment choices in refractory patients. Finally, some biological findings should be briefly highlighted. Among the genes characterizing the resistance to maturation induction, the presence of Meis1 is particularly intriguing. Meis1 is a homeodomain transcription factor that heterodimerizes on DNA and is downregulated during normal myeloid differentiation. It has been demonstrated that Meis1 promotes self-renewal and suppresses granulocyte colony-stimulating factor-induced differentiation in myeloid progenitors immortalized by HoxA9. 40 As a consequence, it has been proposed that Meis1 is part of a molecular switch that regulates progenitor abundance by suppressing differentiation and maintaining self-renewal in response to different subsets of cytokines. It has also been demonstrated that Meis1, interacting with some Hox genes, accelerates leukemic transformation. 41 The high expression of Meis1 in leukemic progenitor cells might explain their almost complete refractoriness to the differentiation inducers. Moreover, the P2Y-like receptor GPR105 is a Gprotein-coupled receptor that participates in the regulation of hematopoietic cells with stem cells characteristics. In fact, an anti-GPR105 antibody selectively defines a subset of hematopoietic cells within the fetal bone marrow that is enriched for G0 cell cycle status and for in vitro stem cell-like multipotential long-term culture capability. 42 In addition, among the genes characterizing the responsiveness to maturation induction, we detected MS4A3 (alias HTm4), a cell-cycle-associated protein expressed in differentiating cells of the hematopoietic system and promotion of the cell cycle arrest at the G1 phase through the dephosphorylation of CDK2 protein. 43 Further studies are needed to assess whether these genes may be considered good candidates for target therapies. Nevertheless, as our signature has been validated by real-time quantitative PCR (RTQPCR) in an independent cohort of patients, like others recently published for different malignancies, 44, 45 it devises a rapid, simple and approved diagnostic tool for the identification of patients eligible for new therapeutic strategies.
